US 11,951,105 B2
Methods of treating psychiatric disorders in obese patients with brexpiprazole
Sundar Srinivasan, Corona Del Mar, CA (US); and Christina Chow Wallen, Seattle, WA (US)
Assigned to LAKE O'HARA LLC, Corona Del Mar, CA (US)
Filed by Lake O'Hara LLC, Corona Del Mar, CA (US)
Filed on Jan. 13, 2022, as Appl. No. 17/575,316.
Application 17/575,316 is a continuation of application No. 17/139,627, filed on Dec. 31, 2020, granted, now 11,229,644.
Prior Publication US 2022/0378781 A1, Dec. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/496 (2006.01); A61P 25/18 (2006.01); A61P 25/24 (2006.01)
CPC A61K 31/496 (2013.01) [A61P 25/18 (2018.01); A61P 25/24 (2018.01)] 17 Claims
 
1. A method of initiating treatment of schizophrenia with brexpiprazole in an obese patient who is not a CYP2D6 poor metabolizer, comprising:
(a) administering 1 mg brexpiprazole twice daily on each of the first 4 days of brexpiprazole treatment;
(b) administering 2 mg brexpiprazole twice daily on each of the next 3 days following step (a); and then
(c) administering a recommended dose of 2-4 mg/day brexpiprazole once daily thereafter;
wherein the obese patient has one or more of the following characteristics:
(i) BMI of at least about 35;
(ii) % IBW of at least about 150%;
(iii) waist size greater than about 42 inches;
(iv) % body fat greater than about 40%;
(v) % android body fat greater than about 40%;
(vi) % gynoid body fat greater than about 40%; or
(vii) total body fat greater than about 40 kg.